WEDNESDAY, 7th DECEMBER 2016 COMMENCING 9:30 AM
AT THE PARK INN HOTEL CARDIFF NORTH, CIRCLE WAY EAST
LLANEDEYRN, CARDIFF, CF23 9XF

AGENDA

1. Welcome and introduction
2. Apologies
3. Declarations of interest
4. Minutes of previous meeting

To protect commercial confidentiality the following appraisals will be held in private

5. Appraisal 1: Full Submission (PAS)
   Fingolimod (Gilenya®) a single disease modifying therapy in highly active relapsing remitting multiple sclerosis for adult patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more Gadolinium enhancing lesions on brain MRI or a significant increase in T2 lesion load as compared to a previous recent MRI

6. Appraisal 2: Instructed Appraisal (WPAS)
   Isavuconazole (Cresemba®) for the treatment of invasive aspergillosis and mucormycosis in patients for whom amphotericin B is inappropriate

7. Appraisal 3: Limited Submission (WPAS)
   Ivacaftor (Kalydeco®) for the treatment of cystic fibrosis in children aged 2 to less than 6 years weighing less than 25 kg who have one of the following gating (class III) mutations in the CFTR gene: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, or S549R

The meeting will now open to the public (approximately 11.30am)

8. Chairman’s report (verbal update)
9. Educational Pack: Material to Support Appropriate Prescribing of Hypnotics and Anxiolytics across Wales
10. Therapeutic Priorities and Clinical Effectiveness Prescribing Programme Summary 2017–2018
11. **Dry Eye Syndrome Guidance**

12. **Appraisal 4 – Full Submission**
   *Ferric maltol (Feraccru®)* for the treatment of iron deficiency anaemia in adults with inflammatory bowel disease

13. **Appraisal 5: Limited Submission**
   *Adalimumab (Humira®)* for the treatment of moderately active Crohn’s disease in paediatric patients (from 6 years of age) who have had an inadequate response to conventional therapy including primary nutrition therapy, and a corticosteroid and/or an immunomodulator, or who are intolerant to or have contraindications for such therapies

**Date of next meeting – Wednesday 15th February 2017 in Cardiff**